Seagull Biosolutions
Seagull BioSolutions is dedicated to developing innovative biological technologies to produce affordable healthcare products based on advances in life sciences. Their mission is to bridge the technology gap in healthcare and make modern medicines accessible globally, utilizing their strength in Measles Vaccine Virus, which is the largest manufacturer of this vaccine in India. They focus on creating new vaccines and therapies that are safe, effective, and economical, with a particular emphasis on the safety and versatility of their platforms like eSAME and Active Virosome Technology.
Industries
Seagull Biosolutions
Pune, Maharashtra, India, Asia
Products
Measles-strain-derived virus seed stock (rescued from cDNA)
Seed virus stocks rescued from full-length antigenome cDNA sequences for research and reagent use.
Membrane protein nanoparticles (membrane-protein-displaying virosomes)
60–80 nm nanoparticles presenting viral or mammalian membrane proteins for use as antigens or discovery reagents.
Pseudovirus reagent kits for neutralization assays (SARS-CoV-2 Spike example)
Reagent kits and pseudovirus preparations expressing pathogen surface glycoproteins to establish pseudovirus neutralization assays and measure neutralizing antibody titers.
Reagent kits, antibodies and recombinant proteins
Supply of research reagent kits and biologic reagents including antibodies and recombinant proteins for assay and reagent development.
Measles-strain-derived virus seed stock (rescued from cDNA)
Seed virus stocks rescued from full-length antigenome cDNA sequences for research and reagent use.
Membrane protein nanoparticles (membrane-protein-displaying virosomes)
60–80 nm nanoparticles presenting viral or mammalian membrane proteins for use as antigens or discovery reagents.
Pseudovirus reagent kits for neutralization assays (SARS-CoV-2 Spike example)
Reagent kits and pseudovirus preparations expressing pathogen surface glycoproteins to establish pseudovirus neutralization assays and measure neutralizing antibody titers.
Reagent kits, antibodies and recombinant proteins
Supply of research reagent kits and biologic reagents including antibodies and recombinant proteins for assay and reagent development.
Services
Oncolytic virus design and production
Contract services to construct and produce recombinant oncolytic viral derivatives for preclinical research and therapeutic development.
Active virosome (membrane-protein nanoparticle) synthesis
Production of non-replicating virosomes that present viral or mammalian membrane proteins for use as antigens, diagnostic reagents or discovery reagents.
Gene cloning and eukaryotic expression services
Cloning and expression of genes in eukaryotic cells, including expression using a viral RdRP-mediated replicon system.
Pseudovirus neutralization assay development and reagent kits
Development and supply of pseudovirus reagents and neutralization assay kits for detection of neutralizing antibodies, including assays for SARS-CoV-2 spike neutralization using ELISA-based readouts.
Preclinical efficacy and ex vivo assay services
Preclinical testing services including animal xenograft efficacy studies and ex vivo immune cell cytotoxicity assays (e.g., PBMC-mediated tumor cell killing).
Oncolytic virus design and production
Contract services to construct and produce recombinant oncolytic viral derivatives for preclinical research and therapeutic development.
Active virosome (membrane-protein nanoparticle) synthesis
Production of non-replicating virosomes that present viral or mammalian membrane proteins for use as antigens, diagnostic reagents or discovery reagents.
Gene cloning and eukaryotic expression services
Cloning and expression of genes in eukaryotic cells, including expression using a viral RdRP-mediated replicon system.
Pseudovirus neutralization assay development and reagent kits
Development and supply of pseudovirus reagents and neutralization assay kits for detection of neutralizing antibodies, including assays for SARS-CoV-2 spike neutralization using ELISA-based readouts.
Preclinical efficacy and ex vivo assay services
Preclinical testing services including animal xenograft efficacy studies and ex vivo immune cell cytotoxicity assays (e.g., PBMC-mediated tumor cell killing).
Expertise Areas
- Viral vector and reverse genetics platform development
- Oncolytic virus therapy development
- Virosome-based antigen and reagent development
- Pseudovirus neutralization assay development
Key Technologies
- Plasmid-based reverse genetics for negative-strand RNA viruses
- Replicon RNA expression systems
- Virosome/pseudovirus production
- Viral RNA-dependent RNA polymerase (RdRP)-mediated expression